Click here to return to the LMHS Home Page

 

Services

Hospital Facilities

Cancer Services

Corporate Health Services

Emergency Services

Heart Services

Kidney Services

Mental Health Services

Neuroscience Services

Nursing Home

Orthopedic and Spine Services

Outpatient Services

Patient Services

Pediatric Services

Physician Locator Services

Primary Care Services

Pulmonary Services

Rehabilitation Services

Sleep Services

Surgical Services

Urgent Care Services

Volunteer Services

Weight Loss Services

Wellness Services

Women's Health Services

Wound Care Services

Hypercoagulable states

Definition

Hypercoagulable state is a condition in which you are more likely to develop blood clots. Blood clots can develop in either arteries or veins.

See also:

Alternative Names

Thromboembolic states; Factor V Leiden; Prothrombin mutation 20210A

Causes

Hypercoagulable states fall into two groups:

  • Inherited
  • Acquired

Inherited means you are born with the tendency to form abnormal blood clots. Common inherited conditions that affect clotting are factor V Leiden and the prothrombin mutation 20210A. Rare inherited conditions include protein C, protein S, and antithrombin III deficiencies.

Acquired means you develop the tendency to form abnormal blood clots later in life. Some medical situations can lead to the formation of abnormal blood clots. These include cancer, recent surgery or trauma, obesity, liver or kidney disease, and use of certain medications.

Situations that can lead to the formation of blood clots include prolonged bedrest, dehydration, poor positioning (such as crossing the legs), sitting for long periods (such as in a plane or car), and long-term use of an intravenous catheter.

Women who take birth control pills or hormone replacement therapy are more likely to develop blood clots. This risk is greatly increased in those who also smoke. The time before, during, and after pregnancy also increases the risk of clots.

References

Schafer AI. Thrombotic disorders: hypercoagulable states. In Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 182.


Review Date: 10/6/2010
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; James R. Mason, MD, Oncologist, Director, Blood and Marrow Transplantation Program and Stem Cell Processing Lab, Scripps Clinic, Torrey Pines, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com
 

home  |  about us  |  services  |  locations  | employmentpatient billing  |  press room  |  events  |  foundation

HIPAA | privacy policy | did you find it? | medical staff | send a link | get well card